Oral Administration of STC-15 in Subjects With Advanced Malignancies

Exclusion Criteria

• •Treatment with any local or systemic antineoplastic therapy within 3 weeks prior to first dose of STC-15
• •Major surgery or radiation within the 3 weeks
• •Immune-related AEs from immunotherapy that required permanent discontinuation
• •Central nervous system (CNS) disease involvement, or prior history of Grade ≥3 drug-related CNS toxicity.
• •Active autoimmune disease that has required systemic treatment in the 2 years prior to Screening